From the Orthopaedic Foot and Ankle Service (Dr. Heijboer, Dr. Lubberts, and Dr. DiGiovanni), Massachusetts General Hospital, Harvard Medical School, and the Orthopaedic Surgery (Dr. Guss and Dr. Johnson), Massachusetts General Hospital, and the Orthopaedic Surgery (Dr. DiGiovanni), Orthopaedic Foot and Ankle Service, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
J Am Acad Orthop Surg. 2019 May 15;27(10):e482-e490. doi: 10.5435/JAAOS-D-17-00787.
Among patients undergoing below-knee orthopaedic surgery, no consensus exists regarding the need for or type of postoperative prophylaxis to prevent venous thromboembolic (VTE) events. The purpose of this study was to assess the incidence and risk factors associated with symptomatic VTE among orthopaedic patients undergoing below-knee surgery who were subject to different types of pharmacologic thromboprophylactic strategies.
A total of 20,043 adult patients who underwent surgery for a below-knee orthopaedic condition between August 2005 and August 2015 were identified. Retrospective chart review recorded patient demographics, comorbid data, and anatomic location of any procedures performed. Multivariable logistic regression analysis was used to determine factors associated with postoperative development of symptomatic VTE among patients receiving various thromboprophylactic regimens.
The incidence of symptomatic VTE in patients who underwent below-knee surgery was 2.5% (492/20,043). For patients who did not receive thromboprophylaxis, the incidence was 1.5% (134/9,127 patients). In this group, risk factors for developing VTE were male sex; nonwhite race; surgery performed below the knee but above the ankle; combination procedures of the forefoot/midfoot, hindfoot/ankle, and/or lower leg; history of VTE; and Charlson Comorbidity Index score greater than 2. Among patients who received an antiplatelet agent, the VTE incidence was 1.7% (33/1,992 patients). The incidence of VTE among patients who received an oral or injectable anticoagulant was 3.6% (325/8,924 patients). In this group, risk factors for developing VTE were male sex; surgery performed below the knee but above the ankle; combination procedures of the forefoot/midfoot, hindfoot/ankle, and/or lower leg; and history of VTE.
Allowing for different types of thromboprophylactic strategies, the results of this study demonstrate a higher rate of symptomatic thromboembolic disease compared with previously reported <1% VTE incidence rates among orthopaedic patients undergoing below-knee surgery. Certain patients are at higher risk for thromboembolic disease after below-knee orthopaedic surgery. This risk was not found to be lowered by thromboprophylaxis as performed in patients in this database. Future research should be directed at determining what the best thromboprophylactic strategies are for lowering this risk.
Therapeutic study level III.
在接受膝下骨科手术的患者中,对于预防静脉血栓栓塞(VTE)事件的术后预防措施的必要性或类型,尚无共识。本研究的目的是评估接受不同类型药物血栓预防策略的膝下手术后骨科患者中出现有症状 VTE 的发生率和相关风险因素。
共确定了 20043 名 2005 年 8 月至 2015 年 8 月间因膝下骨科疾病接受手术的成年患者。回顾性图表审查记录了患者的人口统计学数据、合并症数据以及任何手术的解剖部位。多变量逻辑回归分析用于确定接受各种血栓预防方案的患者术后发生有症状 VTE 的相关因素。
膝下手术后出现有症状 VTE 的患者发生率为 2.5%(492/20043)。未接受血栓预防的患者中 VTE 的发生率为 1.5%(134/9127 例)。在这一组中,发生 VTE 的危险因素包括男性;非白种人;膝关节以下但踝关节以上的手术;前足/中足、后足/踝关节和/或小腿的联合手术;VTE 病史;和 Charlson 合并症指数评分大于 2。接受抗血小板药物的患者中 VTE 的发生率为 1.7%(33/1992 例)。接受口服或注射抗凝剂的患者中 VTE 的发生率为 3.6%(325/8924 例)。在这一组中,发生 VTE 的危险因素包括男性;膝关节以下但踝关节以上的手术;前足/中足、后足/踝关节和/或小腿的联合手术;和 VTE 病史。
考虑到不同类型的血栓预防策略,本研究的结果显示,与之前报道的膝下骨科手术患者<1%的 VTE 发生率相比,有症状血栓栓塞疾病的发生率更高。某些患者在膝下骨科手术后发生血栓栓塞疾病的风险更高。本数据库中的患者并未发现血栓预防可以降低这种风险。未来的研究应致力于确定降低这种风险的最佳血栓预防策略。
治疗研究 III 级。